E-mail| Contact Us| Volunteer| Make A Gift| En Español| Employees



  • Take Control of your Smoking History
  • World-class cancer care made LG Health his top destination
 
 





Learn More

Ann B. Barshinger Cancer Institute



 
Read the Oncology Program Annual Report 2013
 
Oncology Clinical Trials

Oncology Clinical Trials


New hope in the fight against cancer

Thanks to a history of clinical trials research, people with cancer are living longer and with a better quality of life than ever before. Cancer research is advancing at a fast pace and, as a result, researchers are able to develop targeted therapies that are changing the standards of care and saving lives.
 

Some patients may fear that enrollment in a clinical trial means they may receive no treatment at all. The reality is that patients in studies receive either the best treatment currently known for their specific cancer, or a new, and possibly more effective, therapy. Placebos are never used in place of treatment when an existing therapy exists.
 

The Ann B. Barshinger Cancer Institute participates in numerous studies sponsored by the National Cancer Institute through groups such as the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group and the American College of Surgeons Oncology Group.

 

Current oncology treatment trials open for participation:


Site Study Title
BRAIN

Alliance A071102
(currently suspended)

 

Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MBMT Promoter Hypermethylation.

BREAST

CREP

 

Familial Breast Cancer Studies

Novartis
CBYL719C2301

 

Solar-1: A phase III randomized double-blinded, placebo controlled study of alpelisib in combination with fulvestrant for men and post-menopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment.

PALLAS -AFT-05 ABCSG 42 BIG 14-03

 

PALLAS: Palbociclib Collaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

NRG
NRG-BR003

 

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node-Negative Triple-Negative Invasive Breast Cancer

Metamorph
In conjunction with Penn

 

Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

GYN

NRG
NRG-GY004

 

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

HEME

Celgene
AZA-MDS-006

 

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Celgene
CC-486-AML-001

 

A phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in subjects with acute myeloid leukemia in complete remission

BMS CA 209-602

 

An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

LUNG

Genentech/Roche
GO29527

 

A phase iii, open-label, randomized study to investigate the efficacy and safety of atezolizumab(anti-pd l1 antibody) compared with best supportive care following adjuvant cisplatin based chemotherapy in pd l1selected patients with completely resected stage ibiiia nonsmall cell lung cancer

BMS CA 209-955

 

A Phase Ib/II Safety Trial of Nivolumab in Combination with Ipilimumab Administered in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer: CheckMate 955

MELANOMA

BMS Optimize
CA209-357

 

A US multi-site observational study in patients with unresectable and metastatic melanoma

OTHER

PNH Registry

 

Paroxysmal Nocturnal Hemoglobinuria (PNH) Disease registry

ECOG-ACRIN
EAY131-MATCH

 

Molecular Analysis for Therapy Choice (MATCH)


If you have any questions contact oncology research at 717-544-0511

Updated 3/7/2017

 



 
Find A Doctor
Advanced Search
Call 1-888-LGH-INFO
 


Learn More





 

Contact Us:

1-888-LGH-INFO (544-4636) Have a question?
Follow us online.